|Webcasts|November 18, 2022
Tokenization: Practical Applications in Clinical and Real-World Research
Author(s)Evidera
Webinar Date/Time: Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET
Advertisement
Tokenization is becoming more popular with the increase in already tokenized real-world data sets and innovative methods for collecting data. This presentation aims to answer when, why and how patients are tokenized in these newer methods and what happens with the patients and their tokens.
Event Overview:
The ability to link disparate datasets with de-identified or anonymized patient data has existed for decades but has been unrealistic to apply at scale. Tokenization is becoming more popular with the increase in already tokenized real-world data sets and innovative methods for collecting data. When, why, and how patients are tokenized in these newer methods and what happens with the patients and their tokens are still new to the industry. This presentation aims to answer those on-the-ground application questions.
Key Learning Objectives:
- What is tokenization and how does it benefit various stakeholders?
- How are patients tokenized and what are some of the key considerations
- Once patients are tokenized, what do you do with the token and are there other operational considerations?
Speakers:
Mariah Baltezegar
VP and Global Head PPAS & RWE
Specialized Solutions
PPD
VP and Global Head PPAS & RWE
Specialized Solutions
PPD
Mariah Baltezegar leads the Peri- and Post-Approval Studies (PPAS) and Real-World Evidence (RWE) Specialized Solutions team. As an executive member of the PPAS & RWE leadership team, she is responsible for direction of the PPAS & RWE innovation hub and new offering incubation as well as oversight of key operational, commercial and business optimization activities supporting the overall PPAS & RWE business unit. Over the last 20 years, she has held various positions of increasing responsibility across the Thermo Fisher (PPD) enterprise all with a strategic eye for efficiency through process or technology, maximizing the study participant and site experience while ensuring high quality customer results. Mariah completed her Master of Business Administration at the University of North Carolina, Wilmington and holds a bachelor's degree in psychology with a minor in statistics from Winona State University.
Christine Varner
Senior Director, PPAS & RWE Non-
Interventional Studies
PPD
Senior Director, PPAS & RWE Non-
Interventional Studies
PPD
Christine Varner, BS, is a non-interventional studies lead on the Peri- and Post-Approval Studies (PPAS) and Real-World Evidence (RWE) team at Thermo Fisher (PPD). She is a member of the PPAS & RWE Senior Leadership Team, with overall accountability for the strategic talent growth strategy and operational performance of a team of Oversight Directors and Project Leads; drives leadership across performance in relation to financial stewardship, operational delivery and risk management, ensuring compliance with Thermo Fisher (PPD) process. Christine holds a bachelor’s degree in biology with a minor in chemistry from the University of North Carolina at Chapel Hill.
Time and Date:
Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET
Sponsors:
Evidera
PPD
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
September 11th 2025
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
- Addressing the Digital Divide in Decentralized Trials
August 28th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
Latest NIMBLE Study Results Highlight Progress in gMG Research
4
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
5